Drug intelligence / Profile preview

cilnidipine

Development stage
Phase 4
Lead developer
Ajinomoto
Modality
Small Molecules
Administration
Oral
01

Overview

Cilnidipine is a dihydropyridine calcium channel blocker used primarily for the management of hypertension. It uniquely blocks both L-type and N-type voltage-dependent calcium channels. By inhibiting L-type channels in vascular smooth muscle, it induces vasodilation and reduces peripheral vascular resistance, thereby lowering blood pressure. Its action on N-type channels at sympathetic nerve endings inhibits norepinephrine release, further contributing to blood pressure reduction and providing an antisympathetic effect. Cilnidipine is reported to be beneficial for patients with comorbid conditions such as diabetes, albuminuria, chronic kidney disease, and has been studied for use in Raynaud's phenomenon and systemic sclerosis[1][2][3][5][7].

Brand names
AtelecCinalongSiscardNexovasCilacarJiuyueXi LeZhi XinCilnidipine (as a brand in some markets)CILDINE
Other names
cilnidipinocilnidipinum
02

Targets

CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on cilnidipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cilnidipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call